Key Progress and Upcoming Studies for Pelareorep Breast and Pancreatic Cancer Treatments Announced in Preparation for FDA Accelerated Approval Path October 8, 2024
Enrollment completed in Ph 2 proof of concept 065-101 study of fadraciclib in patients with advanced solid tumors and lymphoma; ongoing in T-Cell Lymphoma cohort October 2, 2024
Enrollment discontinued in Ph 3 KarMMa-9 study of Abecma with lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients with suboptimal response after autoSCT October 2, 2024
Deltacel-01 Advanced Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation September 24, 2024
TIL-based cNeT program to be discontinued and Ph 1/2a CHIRON and THETIS clinical trials to be closed September 24, 2024
Two Patients Now Exceeding 1 Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 22, 2024
Patient Recruitment Discontinued in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in NSCLC September 18, 2024
First patient enrolled in triple combination arm of BI-1206, rituximab and Calquence® for the treatment of NHL September 18, 2024
Global Launch of Artemia Ph 3 Registration Study for Cancer Vaccine Tedopi® in 2L NSCLC Cancer Announced September 18, 2024
Trials evaluating ONCT-534 in metastatic CRPC & ONCT-808 in BCL discontinued to explore strategic alternative September 18, 2024
First patient dosed in Investigator-initiated Ph Ib study of iadademstat in 1L AML September 18, 2024
IDMC recommends continuing Ph 3 trial (IOB-013/KN-D18) of IO102-IO103 following a per-protocol interim analysis September 10, 2024
GBM program of INB-200 and INB-400 to be suspended; AML program of INB-100 to be prioritized September 10, 2024
First patient enrolled in Ph 3 SOHO-02 trial of BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations September 3, 2024
Enrollment Completed in Ph 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting September 3, 2024
